Alumis (ALMS) Cash from Financing Activities (2023 - 2025)
Alumis (ALMS) reported Cash from Financing Activities of $1.3 million for Q4 2025, up 26260.0% year-over-year from N/an in Q4 2024, and up 26260.0% on a QoQ basis from $5000.0 in Q4 2024.
Alumis (ALMS) has 3 years of Cash from Financing Activities data on file, last reported at $1.3 million in Q4 2025.
- Quarterly Cash from Financing Activities rose 26260.0% year-over-year to $1.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $236.5 million (down 51.97% YoY) and the FY2025 annual result came in at $2.1 million, down 99.58% from the prior year.
- Cash from Financing Activities grew to $1.3 million in Q4 2025 per ALMS's latest filing, from $5000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $235.2 million in Q3 2024 and bottomed at $5000.0 in Q4 2024.
- The 3-year median for Cash from Financing Activities is $29.7 million (2023), against an average of $74.8 million.
- Peak annual rise in Cash from Financing Activities reached 500221.28% in 2024, while the deepest fall reached 99.98% in 2024.
- Tracing ALMS's Cash from Financing Activities over 3 years: stood at $29.7 million in 2023, then plunged by 99.98% to $5000.0 in 2024, then surged by 26260.0% to $1.3 million in 2025.
- Per Business Quant, the three latest ALMS Cash from Financing Activities figures stand at $1.3 million (Q4 2025), $5000.0 (Q4 2024), and $235.2 million (Q3 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Alumis | 1.84 Bn | 1.75 Bn | - | 1.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.32 Mn |
| Dec 31, 2025 | 1.32 Mn |
| Dec 31, 2024 | 5,000.00 |
| Dec 31, 2024 | 5,000.00 |
| Sep 30, 2024 | 235.15 Mn |
| Sep 30, 2024 | 235.15 Mn |
| Jun 30, 2024 | 128.06 Mn |
| Jun 30, 2024 | 128.06 Mn |
| Mar 31, 2024 | 129.15 Mn |
| Mar 31, 2024 | 129.15 Mn |
| Dec 31, 2023 | 29.72 Mn |
| Dec 31, 2023 | 29.72 Mn |
| Sep 30, 2023 | 47,000.00 |
| Sep 30, 2023 | 47,000.00 |